Live Breaking News & Updates on Prnewswire Cantargia

Stay updated with breaking news from Prnewswire cantargia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Cantargia AB: Cantargia to host R&D Day on new clinical results of nadunolimab in pancreatic cancer on April 24, 2023

LUND, Sweden, April 4, 2023 /PRNewswire/ Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced it will host an R&D Day focusing on new clinical results and biomarker data for ....

Region Flamande , David Liberg , Van Cutsem , Dominique Tersago , Eric Van Cutsem , Prnewswire Cantargia , University Hospitals Gasthuisberg , Vp Research , University Of Warsaw , Belgian Foundation , Nasdaq Stockholm , Division Head , Digestive Oncology , Eric Van , Medical University , Prof Van Cutsem , Belgian Royal Academy ,

Cantargia to host R&D Day on new clinical results of nadunolimab in pancreatic cancer on April 24, 2023

LUND, Sweden, April 4, 2023 /PRNewswire/ Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today. ....

Region Flamande , Van Cutsem , Eric Van Cutsem , Phderic Van Cutsem , Dominique Tersago , David Liberg , Prnewswire Cantargia , University Hospitals Gasthuisberg , Vp Research , Belgian Foundation , University Of Warsaw , Nasdaq Stockholm , Division Head , Digestive Oncology , Eric Van , Medical University , Prof Van Cutsem , Belgian Royal Academy ,

Cantargia treats first triple-negative breast cancer patient in randomized phase II part of TRIFOUR trial

LUND, Sweden, March 14, 2023 /PRNewswire/ Cantargia (Cantargia AB) (Nasdaq Stockholm: CANTA) today. ....

Prnewswire Cantargia , Spanish Breast Cancer Group , Nasdaq Stockholm ,

Cantargia AB: Cantargia presents positive results for nadunolimab at AACR 2023 including new clinical data in pancreatic cancer

LUND, Sweden, March 14, 2023 /PRNewswire/ Cantargia (Cantargia AB) (Nasdaq Stockholm: CANTA) today reported that two abstracts on its lead asset, the antibody nadunolimab (CAN04), have been ....

Dennis Riedl , Prnewswire Cantargia , Clinical Research Excluding Trials , Nasdaq Stockholm , Clinical Research Excluding , Therapeutic Benefit , Monday Apr , Wednesday Apr ,

Cantargia presents positive results for nadunolimab at AACR 2023 including new clinical data in pancreatic cancer

LUND, Sweden, March 14, 2023 /PRNewswire/ Cantargia (Cantargia AB) (Nasdaq Stockholm: CANTA) today. ....

Prnewswire Cantargia , Clinical Research Excluding Trialssession , Nasdaq Stockholm , Therapeutic Benefit , Monday Apr , Wednesday Apr ,